615 related articles for article (PubMed ID: 24856119)
1. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).
Bockhorn M; Uzunoglu FG; Adham M; Imrie C; Milicevic M; Sandberg AA; Asbun HJ; Bassi C; Büchler M; Charnley RM; Conlon K; Cruz LF; Dervenis C; Fingerhutt A; Friess H; Gouma DJ; Hartwig W; Lillemoe KD; Montorsi M; Neoptolemos JP; Shrikhande SV; Takaori K; Traverso W; Vashist YK; Vollmer C; Yeo CJ; Izbicki JR;
Surgery; 2014 Jun; 155(6):977-88. PubMed ID: 24856119
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
[TBL] [Abstract][Full Text] [Related]
3. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
4. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS).
Hartwig W; Vollmer CM; Fingerhut A; Yeo CJ; Neoptolemos JP; Adham M; Andrén-Sandberg A; Asbun HJ; Bassi C; Bockhorn M; Charnley R; Conlon KC; Dervenis C; Fernandez-Cruz L; Friess H; Gouma DJ; Imrie CW; Lillemoe KD; Milićević MN; Montorsi M; Shrikhande SV; Vashist YK; Izbicki JR; Büchler MW;
Surgery; 2014 Jul; 156(1):1-14. PubMed ID: 24856668
[TBL] [Abstract][Full Text] [Related]
5. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
Kang CM; Hwang HK; Choi SH; Lee WJ
Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
[TBL] [Abstract][Full Text] [Related]
6. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
7. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS).
Tol JA; Gouma DJ; Bassi C; Dervenis C; Montorsi M; Adham M; Andrén-Sandberg A; Asbun HJ; Bockhorn M; Büchler MW; Conlon KC; Fernández-Cruz L; Fingerhut A; Friess H; Hartwig W; Izbicki JR; Lillemoe KD; Milicevic MN; Neoptolemos JP; Shrikhande SV; Vollmer CM; Yeo CJ; Charnley RM;
Surgery; 2014 Sep; 156(3):591-600. PubMed ID: 25061003
[TBL] [Abstract][Full Text] [Related]
8. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
9. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma.
Brown ZJ; Shannon AH; Cloyd JM
Minerva Surg; 2024 Jun; 79(3):315-325. PubMed ID: 38385797
[TBL] [Abstract][Full Text] [Related]
11. Borderline resectable pancreatic cancer.
Hackert T; Ulrich A; Büchler MW
Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
[TBL] [Abstract][Full Text] [Related]
12. "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer.
Lombardi P; Silvestri S; Marino D; Santarelli M; Campra D; De Paolis P; Aglietta M; Leone F;
Crit Rev Oncol Hematol; 2019 Jan; 133():17-24. PubMed ID: 30661653
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
[TBL] [Abstract][Full Text] [Related]
14. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.
Isaji S; Mizuno S; Windsor JA; Bassi C; Fernández-Del Castillo C; Hackert T; Hayasaki A; Katz MHG; Kim SW; Kishiwada M; Kitagawa H; Michalski CW; Wolfgang CL
Pancreatology; 2018 Jan; 18(1):2-11. PubMed ID: 29191513
[TBL] [Abstract][Full Text] [Related]
15. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
16. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
[TBL] [Abstract][Full Text] [Related]
17. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
Jang JY; Han Y; Lee H; Kim SW; Kwon W; Lee KH; Oh DY; Chie EK; Lee JM; Heo JS; Park JO; Lim DH; Kim SH; Park SJ; Lee WJ; Koh YH; Park JS; Yoon DS; Lee IJ; Choi SH
Ann Surg; 2018 Aug; 268(2):215-222. PubMed ID: 29462005
[TBL] [Abstract][Full Text] [Related]
18. A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study.
Miura T; Hirano S; Nakamura T; Tanaka E; Shichinohe T; Tsuchikawa T; Kato K; Matsumoto J; Kondo S
Surgery; 2014 Mar; 155(3):457-67. PubMed ID: 24462074
[TBL] [Abstract][Full Text] [Related]
19. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
20. Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients.
Cesaretti M; Abdel-Rehim M; Barbier L; Dokmak S; Hammel P; Sauvanet A
J Visc Surg; 2016 Jun; 153(3):173-81. PubMed ID: 26775202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
